Abstract
Glycoprotein 90K, encoded by the interferon-stimulated gene LGALS3BP, displays broad antiviral activity. It reduces HIV-1 infectivity by interfering with Env maturation and virion incorporation, and increases survival of Influenza A virus-infected mice via antiviral innate immune signaling. Here, we analyzed the expression of 90K/LGALS3BP in 44 hospitalized COVID-19 patients. 90K protein serum levels were significantly elevated in COVID-19 patients compared to uninfected sex- and age-matched controls. Furthermore, PBMC-associated concentrations of 90K protein were overall reduced by SARS-CoV-2 infection in vivo, suggesting enhanced secretion into the extracellular space. Mining of published PBMC scRNA-seq datasets uncovered monocyte-specific induction of LGALS3BP mRNA expression in COVID-19 patients. In functional assays, neither 90K overexpression in susceptible cell lines nor exogenous addition of purified 90K consistently inhibited SARS-CoV-2 infection. Our data suggests that 90K/LGALS3BP contributes to the global type I IFN response during SARS-CoV-2 infection in vivo without displaying detectable antiviral properties.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by funding from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) to C.G. (Collaborative Research Centre SFB900 Microbial Persistence and its Control, Project number 158989968, project C8) and funding of Berlin Institute of Health (BIH) to C.G. T.C.J. is partly funded by NIAID-NIH CEIRS contract HHSN272201400008C. This project was conducted with data from the German National Cohort (NAKO) (www.nako.de). NAKO is funded by the German Federal Ministry of Education and Research (BMBF, project funding reference numbers: 01ER1301A/B/C and 01ER1511D), federal states and the Helmholtz Association with additional financial support by the participating universities and the institutes of the Leibniz Association.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Charite Universitaetsmedizin Berlin gave ethical approval for this work (EA2/066/20).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors. Codes for statistical analyses using linear mixed effects models will be available at https://github.com/GoffinetLab/SARS-CoV-2_90K_patient_study.
